3+2 Pharma LLC has divulged pyrazole-containing CREB-binding protein (CREBBP; CBP)/β-catenin (CTNNB1) interaction inhibitors reported to be useful for the treatment of fibrosis, cancer, aging, neurological, metabolic and dermatological disorders.
Genentech Inc. has identified sodium channel protein type 9 subunit α (Nav1.7) channel blockers reported to be useful for the treatment of pain, depression, pruritus, cardiovascular, respiratory and psychiatric disorders.
Janssen Biotech Inc. and Yuhan Corp. have synthesized substituted aminopyridine compounds acting as EGFR (HER1; erbB1) (mutant) inhibitors reported to be useful for the treatment of cancer and immunological disorders.
Arpeggio Biosciences Inc. has patented phospholipid hydroperoxide glutathione peroxidase, mitochondrial (PHGPx; GPX4) inhibitors reported to be useful for the treatment of cancer.
Researchers at Hangzhou Glubio Therapeutics Co. Ltd. have patented isoindolinone molecular glue degraders that induce DNA-binding protein Ikaros (IKZF1) degradation and are reported to be useful for the treatment of cancer.
A Katholieke Universiteit Leuven patent details 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues that act as viral replication inhibitors potentially useful for the treatment of viral infections.
Research at Medshine Discovery Inc. has led to the development of imidazocyclic compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of diabetes.
Redx Pharma plc has described henyl- and pyridopyrazole derivatives as discoidin domain-containing receptor DDR1 and/or DDR2 inhibitors. They are reported to be useful for the treatment of fibrosis, cancer, transplant rejection, inflammatory, renal, liver and cardiovascular disorders.
RSS